Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mimedx Group (MDXG) Receivables: 2011-2025

Historic Receivables for Mimedx Group (MDXG) over the last 13 years, with Sep 2025 value amounting to $83.6 million.

  • Mimedx Group's Receivables rose 47.20% to $83.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $281.9 million, marking a year-over-year increase of 22.48%. This contributed to the annual value of $59.0 million for FY2024, which is 3.41% up from last year.
  • According to the latest figures from Q3 2025, Mimedx Group's Receivables is $83.6 million, which was up 14.26% from $73.2 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx Group's Receivables peaked at $83.6 million during Q3 2025, and registered a low of $36.1 million during Q1 2021.
  • Moreover, its 3-year median value for Receivables was $57.0 million (2023), whereas its average is $60.3 million.
  • Data for Mimedx Group's Receivables shows a peak YoY surged of 47.20% (in 2025) over the last 5 years.
  • Over the past 5 years, Mimedx Group's Receivables (Quarterly) stood at $41.5 million in 2021, then grew by 12.82% to $46.9 million in 2022, then climbed by 21.65% to $57.0 million in 2023, then climbed by 3.41% to $59.0 million in 2024, then spiked by 47.20% to $83.6 million in 2025.
  • Its Receivables was $83.6 million in Q3 2025, compared to $73.2 million in Q2 2025 and $66.2 million in Q1 2025.